Gilead Sciences Competitors

Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Gilead Sciences and Amgen, as provided by MarketBeat.

Gilead Sciences presently has a consensus target price of $76.1538, indicating a potential upside of 26.86%. Amgen has a consensus target price of $254.08, indicating a potential upside of 13.02%. Given Gilead Sciences' higher possible upside, research analysts clearly believe Gilead Sciences is more favorable than Amgen.

Dividends

Gilead Sciences pays an annual dividend of $2.72 per share and has a dividend yield of 4.5%. Amgen pays an annual dividend of $6.40 per share and has a dividend yield of 2.8%. Gilead Sciences pays out 44.3% of its earnings in the form of a dividend. Amgen pays out 43.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Gilead Sciences has increased its dividend for 1 consecutive years and Amgen has increased its dividend for 1 consecutive years.

Insider and Institutional Ownership

77.9% of Gilead Sciences shares are held by institutional investors. Comparatively, 71.7% of Amgen shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 0.4% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Amgen's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Gilead Sciences and Amgen's gross revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Summary

Amgen beats Gilead Sciences on 12 of the 16 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Gilead Sciences and Vertex Pharmaceuticals, as provided by MarketBeat.

Gilead Sciences presently has a consensus target price of $76.1538, indicating a potential upside of 26.86%. Vertex Pharmaceuticals has a consensus target price of $290.5862, indicating a potential upside of 28.18%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Gilead Sciences.

Volatility and Risk

Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

77.9% of Gilead Sciences shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Gilead Sciences and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Vertex Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Gilead Sciences on 10 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Gilead Sciences and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $76.1538, indicating a potential upside of 26.86%. Regeneron Pharmaceuticals has a consensus price target of $628.52, indicating a potential upside of 22.27%. Given Gilead Sciences' higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Regeneron Pharmaceuticals.

Volatility and Risk

Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Gilead Sciences and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Regeneron Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Regeneron Pharmaceuticals beats Gilead Sciences on 9 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Gilead Sciences and Biogen, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $76.1538, indicating a potential upside of 26.86%. Biogen has a consensus price target of $305.9032, indicating a potential upside of 25.48%. Given Gilead Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Biogen.

Volatility and Risk

Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 78.9% of Biogen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Biogen's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Gilead Sciences and Biogen's gross revenue, earnings per share and valuation.

Biogen has lower revenue, but higher earnings than Gilead Sciences. Biogen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Biogen beats Gilead Sciences on 9 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Gilead Sciences and Seagen, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $76.1538, indicating a potential upside of 26.86%. Seagen has a consensus price target of $176.75, indicating a potential upside of 4.51%. Given Gilead Sciences' higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Seagen.

Volatility and Risk

Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 92.0% of Seagen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 31.1% of Seagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Seagen's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Gilead Sciences and Seagen's gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Seagen on 8 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Gilead Sciences and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Gilead Sciences presently has a consensus price target of $76.1538, indicating a potential upside of 26.86%. Alexion Pharmaceuticals has a consensus price target of $145.25, indicating a potential upside of 17.30%. Given Gilead Sciences' higher possible upside, equities analysts clearly believe Gilead Sciences is more favorable than Alexion Pharmaceuticals.

Volatility and Risk

Gilead Sciences has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 84.2% of Alexion Pharmaceuticals shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Gilead Sciences and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Gilead Sciences and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Alexion Pharmaceuticals. Gilead Sciences is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Alexion Pharmaceuticals beats Gilead Sciences on 10 of the 15 factors compared between the two stocks.